金凯生科 reported revenue of ¥0.31B for the period ended 2026-06-30, -11.2% year on year. Net income was ¥0.03B, a 9.8% net margin on a 38.6% gross margin. The largest revenue line is 销售商品 at 95% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.31B | -11.2% |
| Gross profit | ¥0.12B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.03B | -57.8% |
| Gross margin | 38.6% | Net margin 9.8% |
| Revenue Q/Q | +8.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 销售商品 | ¥0.29B | 94.7% |
| 贸易服务 | ¥0.01B | 4.0% |
| 技术服务 | ¥0.00B | 1.2% |
| 其他(补充) | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.19B | 61.4% |
| R&D | ¥0.02B | 5.3% |
| SG&A | ¥0.06B | 20.8% |
| Tax & other | ¥0.00B | 1.2% |
| Item | Amount |
|---|---|
| Total assets | ¥2.28B |
| Total liabilities | ¥0.15B |
| Shareholders' equity | ¥2.13B |
| Equity / assets | 93.5% |
| Operating cash flow | ¥0.03B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 147% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
固高科技 ・ 德福科技 ・ 智信精密 ・ 尚水智能 ・ 港通医疗 ・ 中远通 ・ 陕西华达 ・ 长华化学 ・ 舜禹股份 ・ 万邦医药 ・ 上大股份 ・ 儒竞科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies